You searched for "intracameral"
Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...
Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?
This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
RPE tears after intravitreal Lucentis
The current hypothesis regarding retinal pigment epithelium (RPE) tears is the contraction and fibrosis in choroidal neovascularisation (CNV) tissue after anti-VEGF therapy can induce rips in the overlying RPE. This South Korean study aimed to identify the association between RPE...
Intravitreal dexamethasone implant for recurrent CMO secondary to IGS
In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...
Long-term outcomes of intravitreal ranibizumab for neovascular AMD
This is a single centre prospective study for the long-term, whole population ‘real-world’ clinical outcomes of ranibizumab therapy in treatment-naïve patients for neovascular age-related macular degeneration (AMD). This study recorded: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA)...
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration
This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...
IVTA use in Behçet’s disease
This study aimed to evaluate the efficacy and safety of intravitreal triamcinolone acetonide (IVTA) injection (4mg/0.1ml) in controlling posterior segment inflammation in patients with Behçet’s disease. Medical records of consecutive patients diagnosed with Behçet’s who underwent IVTA between July 2005...
Culture positivity of needles for IVT injections
Given the worldwide use of intravitreal (IVT) injections, the authors of this paper set out to evaluate the rate of culture positivity of the needles used in routine IVT injections and compare this positivity between 27-gauge and 30-gauge needle tips....
Adjuvant intravitreal dexamethasone implant for persistent CME
In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
